Late-stage chronic kidney disease Market Summary

The Late-stage chronic kidney disease Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).

The Late-stage chronic kidney disease Market companies developing therapies include - AstraZeneca, CinCor Pharma, Novo Nordisk, Boehringer Ingelheim, Eli Lilly and Company, Travere Therapeutics, Vera Therapeutics, Maze Therapeutics, Fresenius Medical Care, Baxter International, DaVita Inc., KBP Biosciences, Judo Bio, DiaMedica Therapeutics, Chinook Therapeutics, and Sentien Biotechnologies, and others.

Late-stage chronic kidney disease Market and Epidemiology Analysis

• Late-stage CKD affects nearly 9–13% of the adult population, with prevalence steadily increasing due to aging populations and rising rates of diabetes and hypertension.
• Moderate-to-severe CKD (Stages 3–5) is estimated to affect approximately 5–7% of the global population, with late-stage CKD accounting for a substantial proportion of healthcare utilization and mortality.
• Diabetes mellitus and hypertension remain the leading causes of late-stage CKD and ESRD worldwide, collectively contributing to the majority of kidney failure cases.
• The prevalence of late-stage CKD rises significantly with age, especially among individuals aged 60 years and older.
• In the United States, more than 35 million adults are estimated to have CKD, while over 808,000 individuals are living with ESRD requiring dialysis or kidney transplantation.

Factors affecting the Late-stage chronic kidney disease Market Growth

Rising Prevalence of Diabetes and Hypertension

The increasing global incidence of diabetes and hypertension, the primary causes of CKD, is significantly driving the growth of the late-stage CKD market. As these chronic conditions continue to rise, the patient population progressing to advanced kidney disease is also expanding.

Growing Aging Population

Elderly individuals are more susceptible to kidney dysfunction and related comorbidities. The rapidly growing geriatric population worldwide is contributing to higher diagnosis rates of late-stage CKD and increasing demand for advanced treatment options.

Advancements in Diagnostic Technologies

Improved screening methods, biomarker-based diagnostics, and early disease detection technologies are enabling quicker identification of CKD progression. Enhanced diagnostic capabilities are supporting timely intervention and expanding the treatment landscape.

Increasing Adoption of Novel Therapies

The introduction of innovative therapies, including SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and targeted biologics, is improving disease management and driving market expansion.

Rising Demand for Renal Replacement Therapies

Growing numbers of patients requiring dialysis and kidney transplantation are contributing significantly to the late-stage CKD market. Expanding dialysis infrastructure and technological advancements in renal care devices further support market growth.

Request a sample to unlock the CAGR for "Late-stage chronic kidney disease Market Forecast"

DelveInsight's "Late-stage chronic kidney disease (CKD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Late-stage chronic kidney disease (CKD), historical and forecasted epidemiology as well as the Late-stage chronic kidney disease (CKD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Late-stage chronic kidney disease (CKD) market report provides current treatment practices, emerging drugs, Late-stage chronic kidney disease (CKD) market share of the individual therapies, current and forecasted Late-stage chronic kidney disease (CKD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Late-stage chronic kidney disease (CKD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Late-stage chronic kidney disease (CKD) market.

Late-stage Chronic Kidney Disease Understanding

Late-stage Chronic Kidney Disease Overview

Late-stage chronic kidney disease (CKD) refers to the advanced stages of kidney impairment, primarily Stage 4 and Stage 5 CKD, where the kidneys lose their ability to efficiently filter waste products, excess fluids, and toxins from the blood. The condition is characterized by progressive and irreversible decline in renal function, leading to severe health complications such as cardiovascular disease, anemia, electrolyte imbalance, bone disorders, and eventual progression to end-stage renal disease (ESRD). Diabetes mellitus and hypertension are the leading causes of late-stage CKD, while factors such as obesity, aging populations, and genetic disorders also contribute to disease prevalence. Common symptoms include fatigue, swelling, nausea, shortness of breath, poor appetite, and fluid retention, significantly affecting patients’ quality of life and increasing the global healthcare burden.

Late-stage Chronic Kidney Disease Diagnosis

The diagnosis of late-stage chronic kidney disease (CKD) involves a comprehensive assessment of kidney function through laboratory testing, imaging studies, and clinical evaluation of disease-related complications. Healthcare professionals typically use blood and urine tests to measure kidney performance, detect protein leakage, and monitor the accumulation of waste products in the body. Diagnostic imaging techniques such as ultrasound and CT scans may also be utilized to evaluate kidney structure and identify underlying abnormalities. In advanced cases, continuous monitoring of cardiovascular health, blood pressure, electrolyte balance, and metabolic complications plays an important role in determining disease severity and guiding treatment decisions. Early and accurate diagnosis of late-stage CKD is essential for slowing disease progression, reducing complications, and improving patient outcomes.

Late-stage Chronic Kidney Disease Treatment

The treatment of late-stage CKD focuses on slowing disease progression, minimizing complications, improving patient quality of life, and preparing individuals for renal replacement therapies when required. Management strategies include the use of antihypertensive medications such as ACE inhibitors and ARBs, SGLT2 inhibitors, phosphate binders, erythropoiesis-stimulating agents, and therapies aimed at controlling diabetes and cardiovascular risk factors. Dietary modifications, including sodium, potassium, and protein restriction, along with lifestyle changes such as smoking cessation and physical activity, are also essential components of treatment. As kidney function declines further, dialysis becomes necessary for many patients, particularly when kidney filtration drops below critical levels.

Late-stage chronic kidney disease (CKD) Epidemiology 

The Late-stage chronic kidney disease (CKD) epidemiology section provides insights about the historical and current Late-stage chronic kidney disease (CKD) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Late-stage chronic kidney disease (CKD) market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings from Late-stage chronic kidney disease Epidemiological Analyses and Forecast

The disease epidemiology covered in the report provides historical as well as forecasted Late-stage chronic kidney disease (CKD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Late-stage chronic kidney disease (CKD) Epidemiology

The epidemiology segment also provides the Late-stage chronic kidney disease (CKD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Late-stage chronic kidney disease Drug Analysis

The drug chapter segment of the Late-stage chronic kidney disease (CKD) report encloses the detailed analysis of Late-stage chronic kidney disease (CKD) marketed drugs and late-stage (Phase-III and Phase-II) Late-stage chronic kidney disease (CKD) pipeline drugs. It also helps to understand the Late-stage chronic kidney disease (CKD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Late-stage chronic kidney disease  Marketed Drugs

The Late-stage chronic kidney disease report provides the details of the marketed products/off-label treatments available for Late-stage chronic kidney disease (CKD) treatment.

Late-stage chronic kidney disease Emerging Drugs

The Late-stage chronic kidney disease report provides the details of the emerging therapies under the late and mid-stage of development for Late-stage chronic kidney disease (CKD) treatment.

Late-stage chronic kidney disease (CKD) Market Outlook

The Late-stage chronic kidney disease (CKD) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Late-stage chronic kidney disease (CKD) market trends by analyzing the impact of current Late-stage chronic kidney disease (CKD) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Late-stage chronic kidney disease (CKD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Late-stage chronic kidney disease (CKD) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Late-stage chronic kidney disease (CKD) market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings from Late- Stage Chronic Kidney Disease Market Forecast Report

This Late- Stage Chronic Kidney Disease section includes a glimpse of the Late-stage chronic kidney disease (CKD) market in 7MM.

The United States Late-Stage Chronic Kidney Disease Market Outlook

This section provides the total Late-stage chronic kidney disease (CKD) market size and market size by therapies in the United States.

EU-5 Countries Late-Stage Chronic Kidney Disease Market Outlook

The total Late-stage chronic kidney disease (CKD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Late-Stage Chronic Kidney Disease Market Outlook

The total Late-stage chronic kidney disease (CKD) market size and market size by therapies in Japan is also mentioned.

Late-stage Chronic Kidney Disease Drugs Uptake

This section focuses on the rate of uptake of the potential Late-stage chronic kidney disease (CKD) drugs recently launched in the Late-stage chronic kidney disease (CKD) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Late-stage chronic kidney disease (CKD) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Late-stage chronic kidney disease (CKD) Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Late-stage chronic kidney disease (CKD) market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Late-stage Chronic Kidney Disease Clinical Trials Activities

The Late-stage chronic kidney disease (CKD) report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Late-stage chronic kidney disease (CKD) key players involved in developing targeted therapeutics.

Late-stage chronic kidney disease Pipeline Development Activities

The Late-stage chronic kidney disease (CKD) report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Late-stage chronic kidney disease (CKD) emerging therapies.

Chronic Kidney Disease Market Access and Reimbursement

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL Views on  Late-stage Chronic Kidney Disease Market

To keep up with current Late-stage chronic kidney disease (CKD) market trends, we take KOLs and SMEs ' opinion working in the Late-stage chronic kidney disease (CKD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Late-stage chronic kidney disease (CKD) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Late-stage Chronic Kidney Disease Market Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Late-stage chronic kidney disease (CKD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Late-stage Chronic Kidney Disease Market Report

• The Late-stage Chronic Kidney Disease Injury Market report covers the descriptive overview of Late-stage chronic kidney disease (CKD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Late-stage chronic kidney disease (CKD) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Late-stage chronic kidney disease (CKD) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Late-stage chronic kidney disease (CKD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The Late-stage Chronic Kidney Disease Injury Market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Late-stage chronic kidney disease (CKD) market

Late-stage Chronic Kidney Disease Market Report Highlights

• In the coming years, the Late-stage chronic kidney disease (CKD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Late-stage chronic kidney disease (CKD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Late-stage chronic kidney disease (CKD). The launch of emerging therapies will significantly impact the Late-stage chronic kidney disease (CKD) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Late-stage chronic kidney disease (CKD)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Late-stage Chronic Kidney Disease Market Report Insights

• Late-stage chronic kidney disease (CKD) Patient Population
• Late-stage Chronic Kidney Disease Injury Therapeutic Approaches
• Late-stage chronic kidney disease (CKD) Pipeline Analysis
• Late-stage chronic kidney disease (CKD) Market Size and Trends
• Late-stage chronic kidney disease (CKD) Market Opportunities
• Impact of upcoming Late-stage chronic kidney disease (CKD) Therapies

Late-stage Chronic Kidney Disease Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Late-stage chronic kidney disease (CKD) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Late-stage Chronic Kidney Disease Injury Market
• Late-stage Chronic Kidney Disease Injury Drugs Uptake

Late-stage Chronic Kidney Disease Market Report Assessment

• Current Late-stage Chronic Kidney Disease Injury Treatment Practices
• Late-stage Chronic Kidney Disease Injury Unmet Needs
• Late-stage chronic kidney disease (CKD) Pipeline Product Profiles
• Late-stage chronic kidney disease (CKD) Market Attractiveness
• Late-stage Chronic Kidney Disease Injury Market Drivers
• Late-stage Chronic Kidney Disease Injury Market Barriers

Key Questions Answered in the Late-stage Chronic Kidney Disease Market Report

Late-stage Chronic Kidney Disease Market Insights:

• What was the Late-stage chronic kidney disease (CKD) drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Late-stage chronic kidney disease (CKD) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Late-stage chronic kidney disease (CKD) market size during the forecast period (2019-2032)?
• At what CAGR, the Late-stage chronic kidney disease (CKD) market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Late-stage chronic kidney disease (CKD) market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Late-stage chronic kidney disease (CKD) market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Late-stage Chronic Kidney Disease Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Late-stage chronic kidney disease (CKD)?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Late-stage chronic kidney disease (CKD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Late-stage chronic kidney disease (CKD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Late-stage chronic kidney disease (CKD)?
• Out of all 7MM countries, which country would have the highest prevalent population of Late-stage chronic kidney disease (CKD) during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Late-stage chronic kidney disease (CKD) treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Late-stage chronic kidney disease (CKD) in the USA, Europe, and Japan?
• What are the Late-stage chronic kidney disease (CKD) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Late-stage chronic kidney disease (CKD)?
• How many therapies are in-development by each company for Late-stage chronic kidney disease (CKD) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Late-stage chronic kidney disease (CKD) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Late-stage chronic kidney disease (CKD) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Late-stage chronic kidney disease (CKD) and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Late-stage chronic kidney disease (CKD)?
• What are the global historical and forecasted market of Late-stage chronic kidney disease (CKD)?

Reasons to buy the Late-stage Chronic Kidney Disease Market Forecast Report

• The Late-stage Chronic Kidney Disease Injury Market report will help in developing business strategies by understanding trends shaping and driving the Late-stage chronic kidney disease (CKD) market
• To understand the future market competition in the Late-stage chronic kidney disease (CKD) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Late-stage chronic kidney disease (CKD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Late-stage chronic kidney disease (CKD) market
• To understand the future Late-stage Chronic Kidney Disease Injury Market market competition in the Late-stage chronic kidney disease (CKD) market